File(s) not publicly available
Validation of linear cerebral atrophy markers in multiple sclerosis
journal contribution
posted on 2023-05-16, 21:51 authored by Butzkueven, H, Kolbe, SC, Jolley, DJ, Brown, JY, Cook, MJ, Ingrid van der MeiIngrid van der Mei, Groom, PS, Carey, J, Eckholdt, J, Rubio, JP, Bruce TaylorBruce Taylor, Mitchell, PJ, Egan, GF, Kilpatrick, THLinear measures of cerebral ventricular enlargement may act as surrogate measures of cerebral atrophy in multiple sclerosis (MS). Linear atrophy markers were measured from routine MRI scans during a population survey of 171 Tasmanian MS patients and 91 healthy controls. Thirty-five Victorian MS clinic patients were recruited as a validation cohort with 14 of these re-assessed 4 years later. In the population survey, we measured three linear brain atrophy markers: inter-caudate distance (ICD), third ventricle width (TVW) and frontal horn width (FHW). TVW (OR 2.0, p = 0.001) and ICD (OR 16.1, p < 0.001) differentiated between MS cases and controls. In the validation study, we correlated the intercaudate ratio (ICR = ICD/brain width) and third ventricular ratio (TVR = TVW/brain width) with brain parenchymal volume. Cross-sectionally, ICR (R = -0.453, p < 0.01) and TVR (R = -0.653, p < 0.01) were correlated with brain parenchymal volume. Longitudinally, brain parenchymal volume loss was inversely correlated with increased ICD (R = -0.77, p < 0.01) and TVW (R = -0.71, p < 0.01). This study shows that ICD measurements obtained from clinical MRI scans are valid brain atrophy measures for use in monitoring MS progression. © 2007 Elsevier Ltd. All rights reserved.
History
Publication title
Journal of Clinical NeuroscienceVolume
15Pagination
130-137ISSN
0967-5868Department/School
Menzies Institute for Medical ResearchPublisher
Churchill LivingstonePlace of publication
United KingdomRepository Status
- Restricted